Senescent cells versus metabolism: two competing strategies reshaping aging interventions

The scientific consensus is crystallizing around a binary strategic framework for aging intervention: nearly every therapeutic advance targets either the senescent cell burden or metabolic dysfunction. Senolytics such as dasatinib plus quercetin eliminate senescent cells outright, while senomorphics like rapamycin suppress their inflammatory secretion; a third approach, senoreversion, attempts epigenetic reprogramming to restore cellular youth. Metabolic interventions—spermidine, α-ketoglutarate, ergothioneine—function as caloric restriction mimetics, activating autophagy and restoring mitochondrial efficiency. Preclinical evidence documents lifespan extension and healthspan improvement across both pathways, positioning them as foundational pillars of precision longevity medicine. For the biohacker and clinic-curious reader, this convergence suggests that the most credible anti-aging interventions operate through specific biological mechanisms, not aspirational promises of rejuvenation.